Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years

Abstract Introduction Upadacitinib (UPA) is a Janus kinase inhibitor that has demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA) with an acceptable safety profile. We investigated laboratory parameter changes in UPA RA clinical trials. Methods Pooled data from six randomized trial...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Christina Charles-Schoeman, Jon T. Giles, Nancy E. Lane, Ernest Choy, Daniel E. Furst, Jiří Vencovský, Anthony G. Wilson, Gerd R. Burmester, Derek Coombs, Sara K. Penn, Nasser Khan, Jillian B. Yee, Kassim Rahawi, Iain B. McInnes
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Adis, Springer Healthcare 2024-01-01
Serie:	Rheumatology and Therapy
Soggetti:	JAK inhibitor Laboratory parameters Rheumatoid arthritis Upadacitinib
Accesso online:	https://doi.org/10.1007/s40744-023-00624-3
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!